Results 31 to 40 of about 311 (111)

Patient and Caregiver Preferences for Once-Weekly Injection Devices for the Treatment of Growth Hormone Deficiency [PDF]

J Endocr Soc
CONTEXT: Once-weekly long-acting growth hormone (GH) analogue (LA-GHA) treatments offer an alternative to once-daily GH injections for the treatment of children and adults with GH deficiency (GHD).
Yuen, Kevin C J, Chen, Jing Voon, Miller, Bradley S, Mason, Brad, Wayser, Graceanne R, Kelepouris, Nicky, Kennedy, Clare   +6 more
core   +2 more sources

Long-acting growth hormone for treating growth hormone deficiency in children: a meta-analysis of randomized controlled trials focusing on changes in body mass index

J Clin Endocrinol Metab
International audienceAbstract Backgound The purpose of this study is to compare the effect of long-acting growth hormone (LAGH) to daily GH on body mass index (BMI) in children with growth hormone deficiency (GHD).
Donzeau, Aurelie, Emeriau, Fabienne, Villanueva, Carine, Linglart, Agnès, Levaillant, Lucie, Teinturier, Cécile, Bouhours-Nouet, Natacha, Rouleau, Stéphanie, Reynaud, Rachel, Perge, Kevin, Castets, Sarah, Coutant, Regis   +11 more
core   +2 more sources

Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study [PDF]

, 2022
Context: Somatrogon is a long-acting recombinant human growth hormone treatment developed as a once-weekly treatment for pediatric patients with growth hormone deficiency (GHD).
Carakushansky, Mauri, Lebl, Jan, Galcheva, Sonya, Maniatis, Aristides K, Palladino, Andrew A, Prakasam, Gnanagurudasan, Dankovcikova, Adriana, Fox, Larry A, Loftus, Jane, De Los Angeles Resa, Maria, Turich Taylor, Carrie, Dattani, Mehul T   +11 more
core   +2 more sources

What do we do now that the long-acting growth hormone is here?

Frontiers in Endocrinology, 2022
In standard 52-week phase III clinical trials, once weekly lonapegsomatropin, somatrogon and somapacitan have been found to yield non-inferior height velocities and similar safety profiles to daily GH (DGH) in children with pediatric growth hormone ...
Bradley S. Miller
doaj   +1 more source

Growth hormone receptor agonists and antagonists: From protein expression and purification to long‐acting formulations

Protein Science, Volume 32, Issue 9, September 2023., 2023
Abstract Recombinant human growth hormone (rhGH) and GH receptor antagonists (GHAs) are used clinically to treat a range of disorders associated with GH deficiency or hypersecretion, respectively. However, these biotherapeutics can be difficult and expensive to manufacture with multiple challenges from recombinant protein generation through to the ...
Yue Wang, Minah Kim, Chantal Buckley, Heather D. Maynard, Ries J. Langley, Jo K. Perry   +5 more
wiley   +1 more source

Long‐acting growth hormone in 2022

Pediatric Investigation, Volume 7, Issue 1, Page 36-42, March 2023., 2023
After successful clinical use of growth hormone (GH) for nearly 70 years, we are now able to use long‐acting GH (LAGH) with identical or even slightly greater efficacy in clinical medicine in GH deficiency in children and adults. ABSTRACT After the isolation of pituitary growth hormone (GH) in 1957, this form of GH, always in limited supply, was the ...
Margaret Steiner, Jacklyn Frank, Paul Saenger   +2 more
wiley   +1 more source

Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan

Drug Design, Development and Therapy
Bradley S Miller,1 Jo Blair,2 Reiko Horikawa,3 Agnès Linglart,4– 7 Kevin CJ Yuen8 1Division of Pediatric Endocrinology, University of Minnesota Medical School, MHealth Fairview Masonic Children’s Hospital, Minneapolis, MN, USA; 2Department of Paediatric ...
Miller BS, Blair J, Horikawa R, Linglart A, Yuen KC   +4 more
doaj   +1 more source

Metformin—‘BRAINS & AIMS’ pharmacological/prescribing principles of commonly prescribed (Top 100) drugs: Education and discussion

British Journal of Clinical Pharmacology, Volume 89, Issue 3, Page 931-938, March 2023., 2023
We review pharmacological/prescribing principles relating to metformin according to our mnemonic framework: ‘BRAINS & AIMS’ (Benefits, Risks, Adverse Effects, Interactions, Necessary prophylaxis, Susceptibilities, Administering, Informing, Monitoring and Stopping): Benefits: Metformin's licensed uses: Type 2 diabetes mellitus (T2DM) treatment ...
Joshua Koslover, Deborah Bruce, Shivani Patel, Andrew J. Webb   +3 more
wiley   +1 more source

Supplementary Material for: Efficacy and Safety of Once-Weekly Somatrogon Compared With Once-Daily Somatropin (Genotropin®) in Japanese Children With Pediatric Growth Hormone Deficiency: Results From a Randomized Phase 3 Study

, 2022
Introduction Somatrogon is a long-acting recombinant human growth hormone being developed as a once weekly treatment for children with growth hormone deficiency (GHD).
Tanaka T. (3272895), Ng D. (8106701), Gomez R. (4105663), Hasegawa Y. (3126297), Pastrak A. (12412600), Castellanos O. (12412603), Okayama A. (12023117), Rosenfeld R.G. (3915239), Yorifuji T. (12412594), Hoshino Y. (11872796), Horikawa R. (12412591), Shima D. (12412597)   +11 more
core   +1 more source

DataSheet_1.pdf

, 2023
IntroductionThe standard of care for pediatric growth hormone deficiency (pGHD) is once-daily recombinant human growth hormone (rhGH). Somatrogon, a long-acting rhGH, requires less frequent, once-weekly, dosing.
Mohamad Maghnie, Roy Gomez (12162539), Roy Gomez, Michel Polak, Jane Loftus (5512790), Andrew Yaworsky, Michel Polak (228888), Andrew Yaworsky (4925512), Roger Lamoureux, Bradley S. Miller, Jane Loftus, Diane M. Turner-Bowker (17280511), Mohamad Maghnie (74636), Roger Lamoureux (17280508), Diane M. Turner-Bowker, Bradley S. Miller (12162545)   +15 more
core   +1 more source